Do Patents Affect Outcomes in Early Stage Investing?
by John Harbison, TCA Venture Group Chairman Emeritus
(originally published by the Angel Capital Association in their Data Insights Series)
In conducting due diligence for early stage companies, we often consider a […]
Preclinical development at 10% of the cost: How Did Reglagene Do It?
Richard Austin is the CEO of Reglagene, a therapeutics company developing brain-penetrating medicines to make breakthroughs in brain cancer treatments. In Today’s “How Did You Do It?” we sat down with Richard to […]
Failures and Fraud in Early-Stage Angel Investing
by John Harbison, TCA Chairman Emeritus
(originally published by the Angel Capital Association in their Data Insights Series)
We all know that investing in early-stage companies is a very risky proposition, and the majority […]
Establishing a Nationwide Contract With Whole Foods: How Did Berri Organics Do It?
Jerome Tse (J) is the founder and CEO of Berri Organics, a southern california company creating all natural, organic electrolyte products. In today’s ‘How Did You […]
Angel’s Angle: Why Did We Invest in Single Pass?
Single Pass is a local OC company solving the unique problem physicians face when conducting biopsies. David Friedman was the Deal Lead for Single Pass. In today’s “Angel’s Angle”, David […]
Generating Pre-Commercial Demand: How Did Single Pass Do It?
Bill Colone is the CEO of Single Pass, is a local Orange County company solving the unique problem physicians face when conducting biopsies. In today’s ‘How Did You Do It?’ We […]